CVie Therapeutics Ltd.
Division of Windtree Therapeutics Inc.
Latest From CVie Therapeutics Ltd.
Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.